{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:28:02Z","timestamp":1789882082239,"version":"4.0.1"},"reference-count":28,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T00:00:00Z","timestamp":1508371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Progression of liver fibrosis in patients with hemoglobinopathies is strongly related to the severity of iron overload and the presence of chronic hepatitis C virus (HCV) infection. Effective iron chelation therapy and HCV infection eradication may prevent liver complications. The European Association for the Study of the Liver guidelines recommend interferon\u2010free regimens for the treatment of HCV infection in patients with hemoglobinopathies. However, data regarding the use of direct\u2010acting antiviral drugs (DAAs) in this patient population are few. This observational study evaluated the safety and efficacy of therapy with DAAs in an Italian cohort of patients with hemoglobinopathies, chronic HCV infection and advanced liver fibrosis. Between March 2015 and December 2016, 139 patients received DAAs and completed 12 weeks of follow up after the end of treatment for the evaluation of sustained virological response (12SVR). The 12SVR (93.5%) was comparable with that typically observed in cirrhotic patients without hemoglobinopathies. Three patients died during the period of observation of causes unrelated to DAAs. One patient did not achieve a virological response and five (3.6%) relapsed during 12 weeks of follow\u2010up after the end of therapy. In addition, patients showed significant reductions in serum ferritin at 12 weeks to levels similar to those observed in a control group of 39 patients with thalassemia major without HCV infection, who adhered to chelation therapy and had no overt iron overload. In conclusion, the use of DAAs appears to be safe and effective in patients with hemoglobinopathies and advanced liver disease due to HCV.<\/jats:p>","DOI":"10.1002\/ajh.24911","type":"journal-article","created":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T08:33:07Z","timestamp":1505896387000},"page":"1349-1355","source":"Crossref","is-referenced-by-count":42,"title":["Treatment of hepatitis C virus infection with direct\u2010acting antiviral drugs is safe and effective in patients with hemoglobinopathies"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2346-9616","authenticated-orcid":false,"given":"Raffaella","family":"Origa","sequence":"first","affiliation":[{"name":"University of Cagliari, Ospedale Pediatrico Microcitemico \u201cA. Cao\u201d Cagliari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Ponti","sequence":"additional","affiliation":[{"name":"Medicina 1, AO Brotzu Cagliari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Filosa","sequence":"additional","affiliation":[{"name":"Cardarelli Hospital Naples Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Galeota Lanza","sequence":"additional","affiliation":[{"name":"Cardarelli Hospital Naples Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Piga","sequence":"additional","affiliation":[{"name":"University of Turin Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Maria","family":"Saracco","sequence":"additional","affiliation":[{"name":"University of Turin Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Pinto","sequence":"additional","affiliation":[{"name":"Centro della Microcitemia e delle Anemie Congenite Galliera Hospital Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Picciotto","sequence":"additional","affiliation":[{"name":"DIMI, University of Genoa Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0116-618X","authenticated-orcid":false,"given":"Paolo","family":"Rigano","sequence":"additional","affiliation":[{"name":"Villa Sofia\u2010Cervello Hospital Palermo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Madonia","sequence":"additional","affiliation":[{"name":"Villa Sofia\u2010Cervello Hospital Palermo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosamaria","family":"Rosso","sequence":"additional","affiliation":[{"name":"Ferrarotto Hospital, Policlinico Vittorio Emanuele Catania Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"D'Ascola","sequence":"additional","affiliation":[{"name":"Centro Microcitemia Reggio Calabria Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8676-6864","authenticated-orcid":false,"given":"Maria Domenica","family":"Cappellini","sequence":"additional","affiliation":[{"name":"University of Milan, Ca Granda Foundation IRCCS Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"D'Ambrosio","sequence":"additional","affiliation":[{"name":"University of Milan, Ca Granda Foundation IRCCS Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Immacolata","family":"Tartaglione","sequence":"additional","affiliation":[{"name":"University of Campania \u201cLuigi Vanvitelli\u201d Naples Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"De Franceschi","sequence":"additional","affiliation":[{"name":"University of Verona Verona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Gianesin","sequence":"additional","affiliation":[{"name":"Centro della Microcitemia e delle Anemie Congenite Galliera Hospital Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6397-4206","authenticated-orcid":false,"given":"Vito","family":"Di Marco","sequence":"additional","affiliation":[{"name":"University of Palermo  Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9833-1016","authenticated-orcid":false,"given":"Gian Luca","family":"Forni","sequence":"additional","affiliation":[{"name":"Centro della Microcitemia e delle Anemie Congenite Galliera Hospital Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Italy for THAlassemia and hepatitis C Advance \u2010 Societ\u00e0 Italiana Talassemie ed Emoglobinopatie (ITHACA\u2010SITE)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,10,19]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-248724"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.09.067"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402355"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2010.05.006"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.1.17"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3167"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12554"},{"key":"e_1_2_8_9_1","first-page":"1136","article-title":"Prevalence and severity of liver disease in patients with b thalassemia major. A single\u2010institution fifteen\u2010year experience","volume":"90","author":"Perifanis V","year":"2005","journal-title":"Haematologica."},{"key":"e_1_2_8_10_1","first-page":"1179","article-title":"Clinical and histological characterization of liver disease in patients with transfusion\u2010dependent beta\u2010thalassemia. A multicenter study of 117 cases","volume":"89","author":"Prati D","year":"2004","journal-title":"Haematologica."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(06)70437-6"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13009"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2010.05544.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.09.001"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12352"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05645.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(06)80585-4"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2016.02.004"},{"key":"e_1_2_8_19_1","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S1665-2681(19)31336-5","article-title":"Efficacy and safety of interferon\u2010based therapy in the treatment of adult thalassemic patients with chronic hepatitis C: a 12 years audit","volume":"12","author":"Vafiadis I","year":"2013","journal-title":"Ann Hepatol."},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61036-9"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306218"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2017.003"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29139"},{"key":"e_1_2_8_24_1","first-page":"e38077","article-title":"Sofosbuvir\u2010containing regimen for the treatment of hepatitis C virus in a patient with sickle\u2010thalassemia: The first case report","volume":"4","author":"Hussein NR.","year":"2017","journal-title":"Int J Infect."},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7635128"},{"key":"e_1_2_8_26_1","unstructured":"Agenzia Italiana del Farmaco. AIFA: aggiornato algoritmo per scelta terapia epatite C cronica in collaborazione con AISF.2015. Available from:http:\/\/www.aifa.gov.it\/content\/aifa-aggiornato-algoritmo-scelta-terapia-epatite-c-cronica-collaborazione-con-aisf. Accessed March 20 2017."},{"key":"e_1_2_8_27_1","unstructured":"University of Liverpool. HEP Drug Interaction Checker. 2017. Available from:http:\/\/www.hep-druginteractions.org\/. Accessed March 20 2017."},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.2001.2822"},{"key":"e_1_2_8_29_1","unstructured":"R Core Team. R: A language and environment for statistical computing.2016. Available from:https:\/\/www.R-project.org\/. Accessed 20 March 2017."}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24911","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T16:28:40Z","timestamp":1695572920000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,19]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1002\/ajh.24911"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24911","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,19]]}}}